Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi: morphosys.com (MOR)
The determination of MorphoSys AG management to focus on its key oncology drug and the advantageous merger with Novartis are evident when monitoring operating profit in monetary terms on the GURU.Markets chart, where the current parameter equals . The business is minimizing Capex, generating revenue through royalties from global partners. The team is currently adapting to new structures while maintaining a high level of confidence in its programs.
Ringkesan rincian data analitis MorphoSys (MOR)
- rega pasar lan target rega analis:
- indikator kapitalisasi bursa perusahaan:
- informasi kapitalisasi buku:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Modal MorphoSys AG|MOR - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal MorphoSys Inc|MOR - Utang perusahaan|Rasio utang-utang marang kapitalisasi buku MorphoSys|MOR - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan MorphoSys|Likuiditas darurat morphosys.com
- rincian bathi lan kelipatan pasar:
MOR - Bathi resik perusahaan|Prakiraan bathi perusahaan MorphoSys AG|MOR - Koefisien rega marang bathi|Rasio prakiraan rega marang bathi morphosys.com|MOR - Rasio rega marang bathi tumrap wutah|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan MorphoSys|MOR - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku MorphoSys|MOR - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan morphosys.com|MOR - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep MorphoSys AG
Analisis kabeh metrik perusahaan:MorphoSys Corporation, MOR
Integrating ESG standards into the development of oncology drugs at MorphoSys AG (MOR) requires significant expenditures on environmental safety and research ethics. Absolute EBITDA captures the actual cash flow from core operations before depreciation and taxes, allowing for the separation of temporary market fluctuations from fundamental business stability. Analyzing absolute EBITDA trends helps investors identify hidden opportunities while ignoring short-term liquidity noise.
Karo sapa MorphoSys AG saingan
Bathi operasional EBITDA BeiGene Oncology ONC|HALO - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi RVMD (revmed.com)|AAPG: Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi CG Oncology Inc (CGON)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi UroGen|Bathi operasional sadurunge ngurangi amortisasi Bicara Corp (BCAX)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Personalis, Inc. (PSNL)|ERAS - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Delcath Systems DCTH|Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi YMAB|AURA - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi CADL|ARAY: Bathi operasional EBITDA|SELLAS Life Sciences Group - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Actuate Therapeutics|Bathi sadurunge bunga, pajak, lan amortisasi Citius Oncology Inc. CTOR|Bathi sadurunge mbayar bunga, pajak, lan amortisasi TuHURA Biosciences, Inc. (HURA)|Pendapatan operasional sadurunge ngurangi amortisasi Protara Tx|Fate Therapeutics, Inc. - Bathi operasional sadurunge ngurangi amortisasi|Aadi Bioscience, Inc. (WHWK) - Bathi sadurunge bunga, pajak, lan amortisasi|TCRX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Pendapatan operasional sadurunge ngurangi amortisasi Champions Oncology CSBR|XBIT (xbiotech.com) - Bathi operasional sadurunge ngurangi amortisasi|CEL-SCI - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|OSTX (OS Therapies Incorporated) - Bathi operasional EBITDA|Bathi operasional EBITDA radiopharmtheranostics.com|Bathi operasional EBITDA ARTV|adlainortye.com (ANL) - Bathi operasional sadurunge potongan amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Veru Pharma VERU|TPST - Bathi operasional sadurunge ngurangi amortisasi|XLO - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi sadurunge bunga, pajak, lan amortisasi Renovaro Inc.|muraloncology.com (MURA) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Kairos Pharma - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|OKUR (OnKure Therapeutics, Inc.) - Bathi operasional EBITDA|Bathi operasional sadurunge ngurangi amortisasi CytoMed (GDTC)|Bathi operasional EBITDA CRIS|Bathi operasional EBITDA apollomicsinc.com (APLM)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Tharimmune THAR|ADVB: Bathi operasional sadurunge amortisasi|Genprex, Inc - Bathi operasional EBITDA|Calidi Biotherapeutics (CLDI) - Bathi operasional sadurunge ngurangi amortisasi|SBFM: Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi Xenetic Biosciences, Inc. (XBIO)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Salarius Pharmaceuticals, Inc.|PPBT: Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi operasional sadurunge ngurangi amortisasi AONC (American Oncology Network)|BGNE (BeiGene Ltd) - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi operasional EBITDA CKPT (Checkpoint Therapeutics)|ELEV - Bathi operasional sadurunge ngurangi amortisasi|ICAD: Bathi operasional sadurunge ngurangi amortisasi|IKNA - Bathi operasional EBITDA|Notable Labs Inc. (NTBL) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Viracta Therapeutics, Inc. - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|NAYA (NAYA Biosciences) - Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi ascentage.com AAPGV
